Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - UBS raised its price target on Gilead Sciences (NASDAQ:GILD) to $112.00 from $108.00 on Friday, while maintaining a Neutral rating on the stock following the company’s strong second-quarter earnings report. According to InvestingPro data, Gilead has delivered an impressive 50.6% return over the past year, with current analysis suggesting the stock is trading near its Fair Value.
Gilead reported second-quarter product sales of approximately $7,054 million, exceeding Bloomberg consensus estimates of $6,977 million. The company’s non-GAAP earnings per share also beat expectations at $2.01 compared to consensus estimates of $1.98. The company maintains strong financial health with a robust 78.3% gross profit margin and operates with a moderate debt level, as shown by InvestingPro’s comprehensive analysis.
The biopharmaceutical company posted revenue beats across its key segments including HIV, oncology, and liver disease treatments. Notable performers included Biktarvy, Descovy, Trodelvy, and Livdelzi, according to UBS.
Gilead raised its 2025 product sales guidance to approximately $28.3-28.7 billion, up from its previous forecast of $28.2-28.6 billion. The company now expects its HIV franchise to grow 3% in 2025, improved from earlier projections of flat growth.
The revised guidance reflects strength in Biktarvy and Descovy sales, partially offset by lower expectations for Veklury. Excluding Veklury, Gilead’s 2025 product sales guidance increased to approximately $27.3-27.7 billion from the previous range of $26.8-26.2 billion.
In other recent news, Gilead Sciences reported its second-quarter 2025 earnings, surpassing Wall Street expectations. The company achieved an earnings per share (EPS) of $2.01, exceeding the forecasted $1.96. Additionally, Gilead’s revenue reached $7.1 billion, surpassing the anticipated $6.97 billion. These results reflect strong performance and have been well-received by investors. The positive earnings and revenue figures are significant developments for the company. Analysts and investors alike are closely watching these financial results, as they provide insight into Gilead’s current business trajectory. While the earnings report is a key highlight, it’s important to note that other factors such as analyst ratings and potential mergers also play a role in shaping investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.